Form 4: InMed Pharmaceuticals Director Andrew Hull Reports Stock Option Conversion
SEC Form 4 Filing
Director Andrew Hull of InMed Pharmaceuticals Inc. reports the conversion of stock options into common shares.
Summary
- On March 5, 2024, a Form 4 filing was submitted to the SEC regarding Andrew Hull, a director of InMed Pharmaceuticals Inc.
- The report details a transaction on January 14, 2024, where employee stock options were converted.
- Specifically, options to purchase 42 common shares were exercised at a price of $307.01 per option.
- The options, originally granted on January 14, 2019, expired on January 14, 2024.
- Following the transaction, Hull directly owns 8,542 common shares.
Sentiment
Score: 5
Explanation: This is a neutral informational document. It simply reports a transaction by a company director.
Industry Context
This filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the holdings of company directors. It's a standard practice for publicly traded companies.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it involves a small number of shares.
Key Dates
| Date | Description |
|---|---|
| 01/14/2019 | Original grant date of the employee stock options |
| 01/14/2024 | Transaction date: Employee stock options converted to common shares; Expiration date of the employee stock options |
| 03/05/2024 | Date of Form 4 filing |
Keywords
Form 4, InMed Pharmaceuticals, Andrew Hull, Stock Options, Beneficial Ownership, Director, Conversion
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.